Diligence memo · auto-generated · as of July 2, 2026
QurAlis Corp
QurAlis Corp looks fair against its niche peers and is active on financing cadence.
Businessfiled
QurAlis Corp operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
QurAlis Corp has raised $118M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $60M on 2022-12-20.
Most recent recorded round closed around 2025-08-21.
Valuation (modeled)modeled
Provath models QurAlis Corp at approximately $118M (range $65M–$153M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.78× the median modeled value of Series C Pharmaceuticals companies in 2025–2027 (26 peers) — value vs value, same stage and era. Within the normal band (78% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 10 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 3.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 93% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 58% of those peers.
Closest niche peers: BlossomHill Therapeutics, Inc., Rivus Pharmaceuticals, Inc., Sparrow Pharmaceuticals, Inc., Arthrosi Therapeutics, Inc., Altesa BioSciences, Inc..
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.